Skip to main content

IDEAYA Biosciences, Inc 8-K, filed Jun 16, 2020

IDEAYA Biosciences, Inc. (IDYA)

8-K 2020-06-16 For: 2020-06-16
View Original
Added on April 12, 2026

About this 8-K

IDEAYA Biosciences, Inc filed this 8-K on June 16, 2020.

Items reported

  • Item 5.07: Shareholder vote results

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2020

IDEAYA Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-38915 47-4268251
(State or other jurisdiction<br><br><br>of incorporation) (Commission<br><br><br>File Number) (IRS Employer<br><br><br>Identification Number)

7000 Shoreline Court, Suite 350

South San Francisco, California 94080 (Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 443-6209

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
--- ---
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
--- ---
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--- ---
Title of each class Trading Symbol Name of each exchange on which registered
--- --- ---
Common Stock, $0.0001 par value per share IDYA The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 16, 2020, IDEAYA Biosciences, Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2020. Only stockholders of record as of the close of business on April 17, 2020, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 20,401,848 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal 1. The election of one Class I director to hold office until the 2023 annual meeting of stockholders or until his respective successor is elected:

Nominee Votes For Votes Withheld Broker<br><br><br>Non-Votes
Yujiro Hata 12,670,530 381,286 3,106,257

Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2020:

Votes For Votes Against Abstentions
16,151,274 1,421 5,378

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEAYA BIOSCIENCES, INC.
Date: June 16, 2020 By: /s/ Yujiro Hata
Yujiro Hata
President and Chief Executive Officer